Global Down Syndrome

2018 Issue 4 of 4

Issue link: https://viewer.e-digitaledition.com/i/1080513

Contents of this Issue

Navigation

Page 10 of 31

one of the leading authorities regarding leukemia in patients with Down syndrome. According to Dr. Crispino, there is a 20-fold increased risk of B-ALL in children and young adults with Down syndrome primarily from ages 5 to 20. B-ALL is an aggressive type of leukemia in which too many B-cell lymphoblasts are found in the bone marrow and blood. Unlike AMKL, reports and studies show that patients with Down syndrome with B-ALL fair worse than their typical counterparts — they have a higher relapse rate, may suffer severe side effects from chemotherapy, and have higher treatment-related mortality. According to Dr. Crispino, part of the problem could be attributed to the attending physicians' lack of adherence to the different chemotherapy protocols for pediatric patients with Down syndrome. Patients with Down syndrome often react poorly to standard chemotherapy for B-ALL, and their "toxicity profile" means more side effects that can result in extreme loss of red and white blood cells and platelets, inflammation in the digestive tract, and even heart failure. "These patients need modified treatment protocols and universal supportive care guidelines that are optimal," says Dr. Crispino. "Including patients with Down syndrome in studies of novel agents, such as immunotherapy and JAK inhibitors, could also help address this problem." Global's lobbying and advocacy efforts, resulting in a $24 million increase in Down syndrome research at the National Institutes of Health (NIH) in 2018, certainly led to an increase in cancer research in this special population, but there is still a long way to go. Dr. Crispino believes we desperately need less toxic and more effective therapies, especially to prevent relapse and treatment- related mortality in patients with Down syndrome. He advocates for research at the NIH that would determine why Down syndrome leads to the increased incidence of leukemia and identify novel drug targets that will lead to development of safer treatments, and for leveraging new technologies that will identify specific genes on chromosome 21 linked to leukemia. While leukemia does not always cause symptoms, Karen Rabin, M.D., Ph.D., Associate Professor of Pediatric Hematology/Oncology and Director of the Leukemia Program at Texas Children's Cancer Center and Baylor College of Medicine, says parents should look out for bone pain, difficulty walking, easy bruising or bleeding, pallor, prolonged and unexplained fevers, and swollen glands in the neck and elsewhere. A complete blood count can detect leukemia in some cases but is not recommended unless symptoms are present, according to Dr. Rabin. Chemotherapy is the standard treatment for most cases of CONTINUED ON PAGE 12

Articles in this issue

Archives of this issue

view archives of Global Down Syndrome - 2018 Issue 4 of 4